.png)
.png)
Latest news from BIA
CEO Update | 30 January 2023
The end of January is always incredibly busy at the BIA, with our first Board meeting of the year welcoming newly elected members, the publication of our annual report into the financing of the sector and of course our Gala Dinner which was a great evening last week. Read more on R&D tax credit campaign at centre of finance work, the Chancellors’ growth speech and more.
CEO Update | 23 January 2023
This week is one of the busiest in the BIA calendar as we host our much looked-forward-to Gala Dinner, get ready to publish last year's finance figures for the sector and gather our new Board for the first time in 2023. More on all this in next week’s Newscast. I look forward to seeing over 600 of you on Thursday night at the Brewery. Read on for AMR national action plan and how CGI blockbuster, Avatar, is in fact important life science work.
Real-world evidence: the panacea for rare diseases?
The publication of the National Institute for Health and Care Excellence’s real-world evidence framework in June 2022 has accelerated discussions about the role that real-world evidence can play in resolving gaps in knowledge and driving forward access to innovations for patients with rare diseases. Senior Policy and Public Affairs Executive, Joe Smale, reflects on a recent BIA-facilitated discussion on the potential of real-world evidence in rare diseases and the importance of patient involvement in future discussions.
How early-stage life sciences companies can improve the odds of attracting funding
The last decade has witnessed a boom in life science start-ups and that pace is set to continue as the search goes on to find improved treatments for diseases including Alzheimer’s and cancer. The science has been backed by record levels of funding, with investment into life sciences in the UK reaching a record £4.5 billion in 2021. Read this blog to learn what start-ups need to know about early-stage funding.
ValiRx signals launch of new strategy with Nottingham laboratories
ValiRx PLC, a life science company focused on early-stage cancer therapeutics and women's health, has taken the lease on laboratory and office facilities at MediCity Nottingham as it embarks on the next stage of its strategy to launch a translational Contract Research Organisation (tCRO).
Arecor announces publication of Phase I data for AT278 in diabetes care
Ultra-concentrated, ultra-rapid acting insulin AT278, a promising candidate in the pursuit of next generation insulins to simplify and improve glycemic control
New Chair of Genomics Advisory Committee appointed by UK BioIndustry Association
The UK Bioindustry Association (BIA) has announced PrecisionLife CEO and Co-founder, Dr Steve Gardner, as the new Chair of the national Genomics Advisory Committee. Dr Gardner will be joined by newly appointed Vice-Chair Danuta Jeziorska, CEO and Co-founder of Nucleome Therapeutics.
FDA accepts Drug Master File, signifying a new milestone for Touchlight’s enzymatic doggybone DNA technology
Touchlight today announced a ground-breaking new milestone for its enzymatic doggybone DNA (dbDNA™), following the FDA acceptance of the Drug Master File (DMF) for doggybone DNA technology. doggybone DNA is the first enzymatic DNA platform with a DMF, representing a significant step towards regulatory adoption. The DMF simplifies the U.S. regulatory process for utilising doggybone DNA and accelerates regulatory filings.
Here's a selection of featured BIA publications. See Resources Hub
UK biotech financing in 2022
The UK’s innovative life sciences and biotech sector secured its fifth best fundraising year ever in 2022, with £1,785 million raised by UK-headquartered public and private companies across the year. While positive, this overall figure masks a mixed picture for the sector.
MMIP Delivering the UK’s Life Sciences Manufacturing Strategy
Influencing and shaping our sector | BIA update: October 2022 - January 2023
BIA response to AMR national action plan call for evidence
The BIA has responded to the Department for Health and Social Care (DHSC)’s call for evidence on the next antimicrobial resistance (AMR) national action plan. Our response was developed with input from a range of BIA members working in the AMR space.
Pharma looks to UK for innovation as global economic uncertainty hits fundraising
As global macroeconomic uncertainty hit fundraising across all sectors, investment in UK biotech fell from the all-time highs seen in 2021, new analysis from the UK BioIndustry Association (BIA) and data and insights company Clarivate shows. However, global pharma and investors looked to UK innovation to strengthen their product pipelines, with UK biotechs being acquired at a premium and others achieving pivotal milestones in their development.
BIA announces new appointments to the BIA Board
The BioIndustry Association (BIA) is pleased to announce the members who have been elected to its Board of Directors and will begin their work this month. BIA members elect five Board Directors, which includes four Corporate and one Other member. The Board Directors were voted for by the BIA’s membership in the weeks leading up to the AGM in October. These members will join the BIA Board from 1 January 2023, for a three-year term, adding to the considerable industry knowledge that the BIA Board can draw on.
BIA announces Bowel Cancer UK as its Charity Partnership for 2023
We are delighted to announce Bowel Cancer UK as its charity partner for 2023. Bowel cancer is the UK's second biggest cancer killer, claiming more than 16,500 lives a year, which is 45 people every day. The partnership with the BIA and its members across the UK’s life sciences ecosystem will play a pivotal role in raising awareness and knowledge which could have a significant and lasting impact on research and the understanding of this disease.
BIA Chairman appointed UK Government’s Life Sciences Investment Envoy
Dr Dan Mahony, Chair of the UK BioIndustry Association (BIA), has been appointed Life Sciences Investment Envoy by the Secretary of State for Business, Energy and Industrial Strategy. The Envoy will champion the UK life sciences sector to national and international investors to help increase investment in scaling life science companies.
The BioIndustry Association (BIA) is the voice of the innovative life sciences and biotech industry, enabling and connecting the UK ecosystem so that businesses can start, grow and deliver world-changing innovation.
Explore opportunities to influence, connect and save with the BIA.
Influence |
Connect |
Save |
|
policymakers, ensuring your voice is heard on the matters that are critical to the success of your organisation |
with the UK ecosystem |
money with the BIA Business Solutions purchasing programme, helping you start, grow and deliver world-changing innovation |
